Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06422143
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-05-15
Brief Title:
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan Sac-TMT MK-2870 in Metastatic Squamous Non-small Cell Lung Cancer NSCLC MK-2870-023
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
2870-023
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None